Monday, 17 April 2017

OncoMed's lung cancer drug fails mid-stage study, shares tumble

(Reuters) - OncoMed Pharmaceuticals Inc said on Monday its experimental lung cancer drug failed a mid-stage study, sending its shares tumbling 30 percent in premarket trading.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)